MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Balance Sheets Overview
Current Ratio
531.33%
Quick Ratio
531.33%
Cash Ratio
45.76%
Debt to Asset Ratio
21.13%
Unit: Thousand (K) dollars
Assets Breakdown
Marketable securities
Cash and cash equivalents
Operating lease right-of-use ass...
Others
Liabilities Breakdown
Additional paid-in capital
Accumulated deficit
Non-controlling interest
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Balance Sheets
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Cash and cash equivalents
4,868
9,644
18,618
4,144
Accounts receivable
2,042
2,042
2,042
-
Contract asset
-
-
0
0
Marketable securities
48,523
33,759
31,091
0
Prepaid expenses and other current assets
1,090
1,646
1,570
811
Total current assets
56,523
47,091
53,321
4,955
Property and equipment, net
525
601
736
922
Operating lease right-of-use asset
3,549
3,941
4,318
4,017
Other assets
246
246
246
245
Total assets
60,843
51,879
58,621
10,139
Accounts payable
1,049
858
309
2,467
Accrued expenses and other current liabilities
3,137
4,706
3,943
2,091
Current portion of deferred revenue
5,123
6,831
6,831
-
Current portion of long-term debt
-
-
0
13,537
Current portion of operating lease liability
1,329
1,460
1,586
1,049
Total current liabilities
10,638
13,855
12,669
19,144
Long-term deferred revenue
0
0
1,708
-
Long-term debt, less current portion
-
-
0
0
Operating lease liability, less current portion
2,220
2,481
2,732
2,968
Total liabilities
12,858
16,336
17,109
22,112
Common stock, value-Common Class A
11
9
9
4
Common stock, value-Common Class B
2
2
2
2
Common stock, value-Common Class C
0
0
0
0
Additional paid-in capital
186,255
168,015
165,578
114,406
Accumulated other comprehensive gain
-30
-8
1
3
Accumulated deficit
-147,004
-139,613
-132,580
-122,275
Total stockholders' (deficit)/equity attributable to rani therapeutics holdings, inc
39,234
28,405
33,010
-7,860
Non-controlling interest
8,751
7,138
8,502
-4,113
Total stockholders' (deficit)/equity
47,985
35,543
41,512
-11,973
Total liabilities and stockholders' equity
60,843
51,879
58,621
10,139
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Balance Sheets
Marketable securities
$48,523K
Cash and cash
equivalents
$4,868K
(-52.35%↓ Y/Y)
Accounts receivable
$2,042K
Prepaid expenses and
other current assets
$1,090K
(27.19%↑ Y/Y)
Total current assets
$56,523K
(410.46%↑ Y/Y)
Operating lease
right-of-use asset
$3,549K
(-19.12%↓ Y/Y)
Property and equipment,
net
$525K
(-54.11%↓ Y/Y)
Other assets
$246K
(-16.04%↓ Y/Y)
Total assets
$60,843K
(260.06%↑ Y/Y)
Total liabilities and
stockholders' equity
$60,843K
(260.06%↑ Y/Y)
Total stockholders'
(deficit)/equity
$47,985K
(624.25%↑ Y/Y)
Total liabilities
$12,858K
(-50.64%↓ Y/Y)
Total stockholders'
(deficit)/equity attributable to...
$39,234K
(803.75%↑ Y/Y)
Non-controlling interest
$8,751K
(344.58%↑ Y/Y)
Total current
liabilities
$10,638K
(-48.42%↓ Y/Y)
Operating lease
liability, less current...
$2,220K
(-30.60%↓ Y/Y)
Accumulated deficit
-$147,004K
(-25.79%↓ Y/Y)
Accumulated other
comprehensive gain
-$30K
(-1100.00%↓ Y/Y)
Additional paid-in capital
$186,255K
(67.38%↑ Y/Y)
Current portion of
deferred revenue
$5,123K
Accrued expenses and
other current...
$3,137K
(19.01%↑ Y/Y)
Current portion of
operating lease liability
$1,329K
(11.77%↑ Y/Y)
Accounts payable
$1,049K
(-41.66%↓ Y/Y)
Common stock,
value-Common Class A
$11K
(266.67%↑ Y/Y)
Common stock,
value-Common Class B
$2K
(0.00%↑ Y/Y)
Buy us a coffee
Rani Therapeutics Holdings, Inc. (RANI)
Rani Therapeutics Holdings, Inc. (RANI)